This inventor holds 2 USPTO granted patents and 5 published patent applications and 3 EPO patents. Top assignee: Mission Therapeutics Limited. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Paul William Thompson - Innovator in Therapeutic Solutions
Introduction
Paul William Thompson is an inventor based in Cambridge, GB. He is currently associated with Mission Therapeutics Limited, where he focuses on developing innovative therapeutic solutions. Despite having no granted patents to his name, Thompson is actively engaged in research and development in the field of medicine.
Latest Patent Applications
Thompson's latest patent applications include:
1. **N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS** - This invention relates to a class of N-cyanopyrrolidines that act as inhibitors of the deubiquitylating enzyme USP30. These compounds have potential utility in various therapeutic areas, including conditions involving mitochondrial dysfunction, cancer, and fibrosis.
2. **N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION** - This application also pertains to a class of N-cyanopyrrolidines with activity as inhibitors of USP30, aimed at addressing mitochondrial dysfunction, cancer, and fibrosis.
Conclusion
Paul William Thompson is a dedicated inventor contributing to the field of therapeutic innovations through his research at Mission Therapeutics Limited. His work on USP30 inhibitors showcases his commitment to addressing critical health challenges.